EquilliumEQ
Market Cap: $31M
About: Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Employees: 45
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.01% less ownership
Funds ownership: 20.04% [Q1] → 20.03% (-0.01%) [Q2]
11% less funds holding
Funds holding: 28 [Q1] → 25 (-3) [Q2]
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
70% less capital invested
Capital invested by funds: $16.3M [Q1] → $4.89M (-$11.4M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 111 / 252 met price target | 471%upside $5 | Buy Reiterated | 19 Aug 2024 |
Financial journalist opinion
Based on 3 articles about EQ published over the past 30 days